{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062007","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.924870+00:00","generated_at":"2026-06-08T06:24:27.602385+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eledon reports Q3 net loss $10.3M ($0.35/sh); cash $59.6M; advances tegoprubart trials","bullets":["Net loss of $10.3M ($0.35 per share) vs $10.5M ($0.73) YoY; R&D spend $7.9M.","Cash & short-term investments $59.6M as of Sept 30, 2023, up from $56.4M at Dec 31, 2022.","Phase 1b data: tegoprubart prevented kidney transplant rejection; mean eGFR >70 at all post-Day 90 timepoints.","First participant dosed in Phase 2 BESTOW trial for kidney transplant rejection; enrollment completion targeted end of 2024.","Tegoprubart used in second-ever pig-to-human heart transplant; appointed new CMO (Eliezer Katz) and two board members."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062007","json":"https://secwatch.observer/filing/0000950170-23-062007.json","markdown":"https://secwatch.observer/filing/0000950170-23-062007.md","text":"https://secwatch.observer/filing/0000950170-23-062007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023062007/0000950170-23-062007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023062007/eldn-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:24:27.602385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c149f278149142e675a6042fd4d2318a2ed72b75","claim":"Eledon Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: net income net loss of $10.3 million, or $0.35 per share, EPS $0.35 per share.","evidence_excerpt":"The company reported a net loss of $10.3 million, or $0.35 per share, for the three months ended September 30, 2023, compared to a net loss of $10.5 million, or $0.73 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023062007/0000950170-23-062007-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Net income","value":"net loss of $10.3 million, or $0.35 per share"},{"label":"EPS","value":"$0.35 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}